March 7 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS ANNOUNCES 33% ENROLLMENT IN SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
BIOXCEL THERAPEUTICS INC: TOPLINE DATA EXPECTED IN SECOND HALF OF 2025
BIOXCEL THERAPEUTICS: SERENITY PHASE 3 SAFETY TRIAL TOPLINE DATA EXPECTED IN H2 2025
Source text: ID:nGNX305GcS
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.